The number of biological/biotechnology-derived proteins used as therapeutic agents is steadily increasing. These products may induce unwanted immune responses, which can be influenced by various factors, including patient- and disease-related factors as well as product-related factors.

 

 

Posted on the EMA website on 1 October 2015